BCL2L1 and cancer: For example, Kolb et al. showed that the BCL-xL degrader PROTAC activates CD8 + T cell-mediated antitumor immune responses via depleting tumor-infiltrating Treg, suggesting that the combination of anticancer PROTACs and ICI may improve cancer treatment [37].